Follow The Filings

GALT Galectin Therapeutics

Galectin Therapeutics earnings company data as of 4:47 AM ET 10/22

  • 0 of 1 EPS beats

History

2 periods, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 13 Nov EPS — — —
Rev — — —
FY2026 Q2 14 Aug EPS -0.09 -0.14 Miss
Rev — — —

Insider trades

Open-market buys and sales by GALT's executives, directors and 10% owners in the last 12 months, from their Form 4s

All GALT insider trades
  • $26K bought by 2 insiders
  • $1.6M sold by 1 insider outside a trading plan
  • $4.6M sold by 4 insiders under 10b5-1 plans
  1. Khurram Jamil Chief Medical Officer
    Planned sale
    $83K 16,250 shares at $5.13 100% of stake
    Traded Jul 14 Filed Jul 16
    ↗
  2. Harold H. Shlevin Director
    Planned sale
    $151K 30,000 shares at $5.03 82% of stake
    Traded Jun 26–29 Filed Jun 30
    ↗
  3. Khurram Jamil Chief Medical Officer
    Planned sale
    $262K 52,037 shares at $5.04 100% of stake
    Traded Jun 26–29 Filed Jun 30
    ↗
  4. Khurram Jamil Chief Medical Officer
    Planned sale
    $24K 7,557 shares at $3.14 100% of stake
    Traded Jun 23 Filed Jun 25
    ↗
  5. Khurram Jamil Chief Medical Officer
    Planned sale
    $1,761 568 shares at $3.10 100% of stake
    Traded May 26 Filed May 28
    ↗
  6. Kary Eldred Director
    Buy
    $810 300 shares at $2.70 +0.5% to stake
    Traded Feb 6 Filed Feb 9
    ↗
  7. Joel Lewis CEO
    Planned sale
    $321K 84,000 shares at $3.82 9.2% of stake
    Traded Jan 2–6 Filed Jan 6
    ↗
  8. Jack W Callicutt CFO
    Planned sale
    $233K 60,000 shares at $3.89 89% of stake
    Traded Jan 2–6 Filed Jan 6
    ↗
  9. Khurram Jamil Chief Medical Officer
    Planned sale
    $232K 60,000 shares at $3.87
    Traded Jan 2–6 Filed Jan 6
    ↗
  10. Khurram Jamil Chief Medical Officer
    Planned sale
    $33K 8,125 shares at $4.07 100% of stake
    Traded Dec 31, 2025 Filed Jan 5
    ↗
  11. Kevin D Freeman Director
    Buy
    $20K 5,500 shares at $3.55 +11% to stake
    Traded Dec 23, 2025 Filed Dec 23, 2025
    ↗
  12. Kary Eldred Director
    Buy
    $2,611 700 shares at $3.73 +1.1% to stake
    Traded Dec 23, 2025 Filed Dec 23, 2025
    ↗
  13. Joel Lewis CEO
    Planned sale
    $55K 7,829 shares at $7.06 0.9% of stake
    Traded Dec 17, 2025 Filed Dec 19, 2025
    ↗
  14. Khurram Jamil Chief Medical Officer
    Planned sale
    $137K 19,442 shares at $7.04 100% of stake
    Traded Dec 17, 2025 Filed Dec 19, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 53 option exercises, 2 other transactions, and 1 stock grant.

SEC filings

Recent issuer filings from EDGAR, 14 shown.

Filed Form Detail Links
DEF 14A Filing Doc
DEFA14A Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
SCHEDULE 13D/A — Filing Doc
8-K 3.02,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 5.02,9.01 Filing Doc
8-K 5.02 Filing Doc
8-K 5.02 Filing Doc

Source: SEC EDGAR submissions, updated 4 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.